$3.13
▲ +1.9% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Overview
52-week range
$2.32
$5.46
26% of range
Avg surprise (last 2)
+20.0%
Avg reaction (last 1)
+1.6%
100% positive
Latest IV / EM
448%
EM ±87.7% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu Apr 30, 2026 | Apr 2026 | $-0.07 | — | — | — | — | financials |
| Sat Jan 31, 2026 | Jan 2026 | $-0.08 | — | — | — | — | financials |
| Wed Sep 10, 2025 | Jul/2025 | $-0.07 | $-0.10 | +30.0% | — | — | earnings |
| Thu Jul 31, 2025 | Jul 2025 | $-0.07 | — | — | — | — | financials |
| Wed May 28, 2025 | Apr/2025 | $-0.09 | $-0.10 | +10.0% | — | +1.6% | earnings |
| Fri Jan 31, 2025 | Jan 2025 | $-0.10 | — | — | — | — | financials |
| Wed Jul 31, 2024 | Jul 2024 | $-0.10 | — | — | — | — | financials |
| Tue Apr 30, 2024 | Apr 2024 | $-0.10 | — | — | — | — | financials |
| Wed Jan 31, 2024 | Jan 2024 | $-0.10 | — | — | — | — | financials |
| Mon Jul 31, 2023 | Jul 2023 | $-0.08 | — | — | — | — | financials |
| Sun Apr 30, 2023 | Apr 2023 | $-0.07 | — | — | — | — | financials |
| Tue Jan 31, 2023 | Jan 2023 | $0.08 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Sep 9, 2026 | Jul/2026 | OTHER | -$0.08 | -$0.07 | -14.3% |
Financials
Income statement (quarterly)
| Metric | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-3M | $-3M | — | $-2M | $-3M | $-3M | — | $-4M |
| Net income | $-3M | $-3M | — | $-2M | $-3M | $-3M | — | $-3M |
| EPS (diluted) | $-0.07 | $-0.08 | — | $-0.07 | $-0.09 | $-0.10 | — | $-0.10 |
Balance sheet (quarterly)
| Metric | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1M | $2M | $1M | $1M | $2M | $1M | $1M | $1M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $15M | $15M | $16M | $17M | $17M | $19M | $21M | $23M |
| Total assets | $15M | $15M | $16M | $18M | $17M | $19M | $22M | $23M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $2M | $1M | $2M | $2M | $2M | $2M | $3M | $2M |
| Total equity | $14M | $14M | $15M | $17M | $15M | $17M | $20M | $21M |